Evidence map›Paper›PMID 41492400›Full record

ArticleExploratory research in clinical and social pharmacy2026

Patients' perspectives and experiences regarding medication reviews: A cross-sectional survey study.

Charlotte Falke, Fatma Karapinar-Çarkit, Wilma Knol, Marcel Bouvy, Toine Egberts, Thomas Kempen, Marcia Vervloet, Mette Heringa

Abstract read
In one paragraph

Article in Exploratory research in clinical and social pharmacy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Charlotte FalkeDivision of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Faculty of Science, Utrecht University, Utrecht, the Netherlands.
Fatma Karapinar-ÇarkitDepartment of Clinical Pharmacy & Toxicology, Maastricht University Medical Center+, Maastricht, the Netherlands.
Wilma KnolGeriatric Medicine Department and Expertise Centre Pharmacotherapy in Old Persons, University Medical Centre Utrecht, Utrecht University, Utrecht, the Netherlands.
Marcel BouvyDivision of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Faculty of Science, Utrecht University, Utrecht, the Netherlands.
Toine EgbertsDivision of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Faculty of Science, Utrecht University, Utrecht, the Netherlands.
Thomas KempenDivision of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Faculty of Science, Utrecht University, Utrecht, the Netherlands.
Marcia VervloetNivel, Netherlands Institute for Health Services Research, Utrecht, the Netherlands.
Mette HeringaSIR Institute for Pharmacy Practice and Policy, Leiden, the Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Medication reviews are conducted worldwide to reduce medication-related problems. However, real-world patient perspectives and experiences remain underexplored. This study aimed to explore patients' perspectives and experiences regarding medication reviews and to assess differences across levels of polypharmacy. Methods: A cross-sectional online survey was conducted among a panel of Dutch pharmacy visitors. Topics included perspectives and experiences regarding medication reviews. Descriptive statistics were used, and Chi-square tests were used to assess differences between levels of polypharmacy (non-polypharmacy: 1-4 medications; polypharmacy: 5-9 medications; hyperpolypharmacy: ≥10 medications). Results: Among 4395 respondents (median age: 71; 43 % female), 48 % were aware of the existence of medication reviews, and 85 % deemed these important. Patients valued discussing the appropriateness, efficacy, side-effects, and risks of medication more than practical medication-related issues. These perspectives were consistent across polypharmacy levels. Overall, 1176 patients (27 %) had experienced a review (non-polypharmacy: 22 %; polypharmacy: 29 %; hyperpolypharmacy: 39 %). Of these, 92 % felt able to ask questions, and 62 % felt treatment options were sufficiently discussed. Patients reported that their review resulted in better medication understanding (68 %), increased confidence in medication usage (65 %), and fewer health issues (40 %). Patients with non-polypharmacy reported improvements in follow-up agreements (9 %) and involvement of secondary healthcare providers (11 %) less frequently than those with polypharmacy (14 %/15 %) and hyperpolypharmacy (19 %/26 %). Conclusion: Most patients valued medication reviews, yet only half were aware of their existence. Generally, levels of polypharmacy hardly impacted patient perspectives. Based on patients' experiences, shared decision-making, follow-ups, and multidisciplinary approaches could be better implemented in medication reviews.

Indexed as

Medication reviewPatients' perspectivesPolypharmacyPrimary care

Identifiers

PMID41492400
PMCPMC12765331

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.